Stage 3 Ovarian Cancer Care: Treatment & Expert Insights

What is Stage 3 Ovarian Cancer?

Stage 3 ovarian cancer is characterized by advanced intra-abdominal disease, where cancerous cells extend beyond the pelvis into the upper abdomen or into the retroperitoneal lymph nodes. This stage accounts for 60-70% of ovarian cancer diagnoses and has a 39-50% five-year survival rate following optimal treatment. According to FIGO staging, Stage 3 (T1-3N1/N2S1-2M0) includes cases with microscopic (3A1) or gross (>2 cm, 3C) peritoneal metastases that are located above the pelvic brim, or with positive para-aortic lymph nodes. Comprehensive surgical staging is essential since preoperative imaging often underestimates the extent of the disease in 30-40% of cases.

Stage 3A and Stage 3C

• •Stage 3A
  Involves microscopic peritoneal metastases outside of the pelvis (3A1) or positive retroperitoneal lymph nodes (3A2) while the upper abdomen appears grossly normal. Detection requires infracolic omentectomy and 20 or more peritoneal biopsies.
• •Stage 3C
  Characterized by gross upper abdominal implants larger than 2 cm, typically affecting the omentum, mesentery, or diaphragmatic surfaces. This stage necessitates extensive cytoreductive surgery for optimal debulking, aiming for less than 1 cm of residual disease.

Causes & Risk Factors of Stage 3 Ovarian Cancer

The causes and risk factors for Stage 3 ovarian cancer are similar to those for earlier stages and include BRCA1/2 germline mutations (which hold the highest stage-specific risk), Lynch syndrome, age (with peak incidence around 55-65), endometriosis (especially the clear cell subtype), and nulliparity. Stage 3 cancer usually represents a progression from undetected Stage 1 or 2 micro-metastases, reflecting a diagnostic delay rather than distinct carcinogenesis. Rapid peritoneal dissemination accounts for the predominance of high-grade serous histology in this stage.

Signs & Symptoms of Stage 3 Ovarian Cancer

• •Common Early Signs
  Progressive abdominal distension due to ascites (70%), early satiety, bloating, pelvic pressure, and new-onset constipation or diarrhea.
• •Less Common Symptoms
  Malignant bowel obstruction (10-15%), pleural effusion (5% in Stage 3C), peripheral edema from lymphatic obstruction, and paraneoplastic syndromes like hypercalcemia.

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Diagnosis of Stage 3 Ovarian Cancer

Diagnosis is typically confirmed through elevated CA-125 levels (often >500 U/mL), complex ascites on ultrasound or CT that shows omental caking, peritoneal thickening, or diaphragmatic nodules. A diagnostic paracentesis can confirm cytology. A preoperative Peritoneal Cancer Index (PCI) assessment guides the candidacy for neoadjuvant chemotherapy. Definitive staging through exploratory laparotomy confirms the extent of disease (3A-3C) via infracolic omentectomy, peritoneal stripping, diaphragmatic stripping, splenectomy, and para-aortic lymphadenectomy.

Treatment Process of Stage 3 Ovarian Cancer

• •Primary Cytoreductive Surgery (PCS)
  The goal is to achieve R0 status (no visible residual disease) in fit patients. This involves total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and potentially bowel resection.
• •Neoadjuvant Chemotherapy (NACT)
  Involves 3-4 cycles of carboplatin and paclitaxel for unresectable disease or patients with poor performance status, followed by interval cytoreduction (ICR).
• •Adjuvant Therapy
  Includes 6 cycles of platinum-taxane chemotherapy, with potential use of bevacizumab or PARP maintenance (especially for HRD tumors). Intraperitoneal chemotherapy is also considered superior for optimal debulking.

Why Choose Everhope for Stage 3 Ovarian Cancer Treatment

Everhope Oncology has achieved over an optimal cytoreduction rate due to specialized surgeons, real-time HRD/PARP eligibility assessments through FoundationOne genetic profiling, and postoperative IV nutritional optimization. This ensures patients can progress from NACT to ICR without treatment interruptions.